Description: Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.
Home Page: www.ibtherapeutics.com
Bryggargatan 10
Stockholm,
111 21
Sweden
Phone:
46 7 62 19 37 38
Officers
| Name | Title |
|---|---|
| Mr. Staffan Stromberg Ph.D. | Chief Exec. Officer |
| Mr. Robert Molander | Chief Commercial Officer |
| Ms. Maria Ekdahl | Chief Financial Officer |
| Mr. Anders Kronström | Chief Operating Officer |
| Prof. Jonas Rastad M.D., Ph.D. | Chief Medical Officer & Chief Scientific Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.721 |
| Price-to-Sales TTM: | 8324.107 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 10 |